Latest topics page 38
Topics ordered by most recent activity across all 71 subcategories.
1,535 topics · page 38 of 52
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Interpreting a composition change that is within the error bars
On the subject in the title: Interpreting a composition change that is within the error bars Working notes rather than a conclusion. Longitudinal report with the method stated, because a number without a…
|
+18 | 22 | 5.8k | 12mo |
|
Sodium, potassium and magnesium when intake drops
On the subject in the title: Sodium, potassium and magnesium when intake drops Working notes rather than a conclusion. Longitudinal report with the method stated, because a number without a method is not a…
|
+73 | 78 | 56k | 12mo |
|
Comparators chosen for regulatory reasons rather than clinical ones — one year on
Comparators chosen for regulatory reasons rather than clinical ones — one year on — setting out what I have, and where I think it stops being reliable. Session topic: SURMOUNT-2 ( Lancet , 2023). Please read…
|
+82 | 87 | 1.1k | 12mo |
|
Journal club: STEP 8 and the fairness of the comparator dose
Journal club: STEP 8 and the fairness of the comparator dose — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 8 ( JAMA , 2022) and finding…
|
+2 | 6 | 39k | 12mo |
|
[2026 update] Citation sweep results: how many references did not say what was claimed
Citation sweep results: how many references did not say what was claimed Writing it up because I had to work it out twice and would rather nobody else did. Nominating something for promotion into the…
|
+41 | 45 | 47k | 12mo |
|
Cagrilintide molecular characteristics and analytical considerations
Cagrilintide molecular characteristics and analytical considerations — setting out what I have, and where I think it stops being reliable. I have seen SURMOUNT-2 ( Lancet , 2023) cited in support of a claim I…
|
4 | 41k | 12mo | |
|
Coming back to: Amylin analogue mechanism: satiety signalling separate from GLP-1
On the subject in the title: Amylin analogue mechanism: satiety signalling separate from GLP-1 Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a claim I…
|
+27 | 31 | 671 | 12mo |
|
Food effects on oral incretin absorption: what is documented
On the subject in the title: Food effects on oral incretin absorption: what is documented Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…
|
2 | 4.4k | 12mo | |
|
Second pass at: Reading a combination trial: attributing effect to components
Second pass at: Reading a combination trial: attributing effect to components — setting out what I have, and where I think it stops being reliable. I have seen SURMOUNT-2 ( Lancet , 2023) cited in support of…
|
+39 | 43 | 7.3k | 12mo |
|
Revisiting: What to include when your question involves arithmetic
Revisiting: What to include when your question involves arithmetic — setting out what I have, and where I think it stops being reliable. Question in the title. Context below, and I have tried to include the…
|
+21 | 25 | 384 | 12mo |
|
Regression to the mean in progress reports
On the subject in the title: Regression to the mean in progress reports Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before posting; the discussion…
|
+30 | 34 | 49k | 12mo |
|
Import rules for personal quantities, by jurisdiction, dated
On the subject in the title: Import rules for personal quantities, by jurisdiction, dated Working notes rather than a conclusion. Structured report rather than an opinion, following the format the maintainers…
|
3 | 60k | 12mo | |
|
Revisiting: Early satiety becoming a problem rather than a benefit
On the subject in the title: Revisiting: Early satiety becoming a problem rather than a benefit Working notes rather than a conclusion. A question about technique rather than about dose. I have been doing the…
|
2 | 14k | 12mo | |
|
Why quantitation is the hard part, not detection
Why quantitation is the hard part, not detection I have a specific reason for asking rather than idle curiosity, and the context is below. Posting the method first, because I know what the first three replies…
|
+11 | 15 | 27k | 12mo |
|
A field-by-field walk through a certificate of analysis
Posting this under the heading it deserves: A field-by-field walk through a certificate of analysis Everything below is what sits behind that. A documentation question rather than an analytical one. I have a…
|
+136 | 147 | 1.8k | 12mo |
|
Forced degradation studies: designing one that is informative — does this still hold?
The question in the title: Forced degradation studies: designing one that is informative — does this still hold? I will give what I have already checked below so nobody repeats it. A documentation question…
|
+37 | 41 | 1.2k | 12mo |
|
Second pass at: Pharmacy supply in the UK and the questions you will be asked
Second pass at: Pharmacy supply in the UK and the questions you will be asked Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail…
|
+46 | 53 | 14k | 12mo |
|
Retatrutide phase 2 in type 2 diabetes: the Lancet paper
On the subject in the title: Retatrutide phase 2 in type 2 diabetes: the Lancet paper Working notes rather than a conclusion. I have seen STEP 2 ( Lancet , 2021) cited in support of a claim I do not think it…
|
+12 | 16 | 50k | 12mo |
|
[2026 update] Constipation management, with a dietitian's contribution
Constipation management, with a dietitian's contribution — setting out what I have, and where I think it stops being reliable. A question about technique rather than about dose. I have been doing the same…
|
+6 | 10 | 812 | 12mo |
|
A 5 mg vial and a 0.25 mg dose: the arithmetic in full — the long version
On the subject in the title: A 5 mg vial and a 0.25 mg dose: the arithmetic in full — the long version Working notes rather than a conclusion. Reporting something rather than asking about it, in case the…
|
+160 | 165 | 1.9k | 12mo |
|
A supplier that answers analytical questions with restated claims
On the subject in the title: A supplier that answers analytical questions with restated claims Working notes rather than a conclusion. A logistics question, since the answers here are usually better than…
|
+107 | 118 | 45k | 12mo |
|
Ipamorelin selectivity claims and where they came from
Ipamorelin selectivity claims and where they came from — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a claim I do not…
|
+51 | 56 | 8.8k | 12mo |
|
A newcomer's list of things that confused me, and the fixes
A newcomer's list of things that confused me, and the fixes — setting out what I have, and where I think it stops being reliable. Question in the title. Context below, and I have tried to include the things…
|
+9 | 13 | 34k | 12mo |
|
A side-effect grading scheme this community uses, and its limits
Posting this under the heading it deserves: A side-effect grading scheme this community uses, and its limits Everything below is what sits behind that. Reporting something rather than asking about it, in case…
|
+1 | 5 | 3.8k | 12mo |
|
Follow-up: The topic list is dense — is that deliberate?
The question in the title: The topic list is dense — is that deliberate? I will give what I have already checked below so nobody repeats it. Nominating something for promotion into the documentation commons.…
|
4 | 23k | 12mo | |
|
Journal club: SURMOUNT-1, read without the press release
Journal club: SURMOUNT-1, read without the press release Writing it up because I had to work it out twice and would rather nobody else did. Session topic: STEP 1 ( N Engl J Med , 2021). Please read it before…
|
+139 | 157 | 66k | 12mo |
|
Discussing something you have already been doing — the long version
Discussing something you have already been doing — the long version Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The…
|
+14 | 18 | 58k | 12mo |
|
Titrating on tolerability rather than on the calendar
On the subject in the title: Titrating on tolerability rather than on the calendar Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I am asking rather…
|
2 | 31k | 13mo | |
|
Journal club: the CagriSema phase 2 combination paper — a second dataset
Journal club: the CagriSema phase 2 combination paper — a second dataset — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a…
|
+74 | 79 | 2.3k | 13mo |
|
Consistent declarations and why they matter more than clever ones — a second dataset
On the subject in the title: Consistent declarations and why they matter more than clever ones — a second dataset Working notes rather than a conclusion. A logistics question, since the answers here are…
|
2 | 4.1k | 13mo |